摘要
目的探讨布地奈德福莫特罗联合孟鲁司特钠对支气管哮喘急性发作期患者血清嗜酸性粒细胞趋化因子-2 (eotaxin-2)、白细胞介素-33(IL-33)水平的影响。方法以2019年1月至2020年6月本院收治的60例支气管哮喘急性发作期患者作为研究对象,按照投掷法随机设为A组(31例)与B组(29例),B组接受布地奈德福莫特罗治疗,A组在B组基础上加用孟鲁司特钠片。记录两组疗效及症状改善时间,并对比治疗前、后两组肺功能相关指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、峰值呼气流速(PEF)]及血清eotaxin-2、IL-33水平。结果 A组总有效率高于B组(90.32%vs.68.97%,P<0.05);A组治疗后喘息、胸闷、咳嗽改善时间较B组缩短(P<0.05);两组治疗后血清eotaxin-2、IL-33水平比治疗前降低,且A组低于B组(P<0.05);两组治疗后FVC、FEV1%、PEF比治疗前升高,且A组高于B组(P<0.05)。结论支气管哮喘急性发作期患者给予布地奈德福莫特罗粉吸入剂联合孟鲁司特钠的疗效显著,能够有效改善患者临床症状及肺功能,降低血清eotaxin-2、IL-33水平。
Objective To explore the influence of budesonide formoterol combined with montelukast sodium on serum eotaxin-2 and interleukin-33(IL-33) levels in patients with acute attack of bronchial asthma.Methods Sixty patients with acute attack of bronchial asthma in our hospital from January 2019 to June 2020 were selected and randomly divided into group A(n=31) and group B(n=29).Group B was treated with budesonide formoterol, while group A was treated with montelukast sodium tablets on the basis of the treatment for group B.Curative effect and symptom improvement time were recorded.Lung function-associated indexes [forced vital capacity(FVC),forced expiratory volume in one second(FEV1),peak expiratory flow(PEF)],and serum eotaxin-2 and IL-33 levels before and after treatment were compared between the two groups.Results The response rate in group A was higher than that in group B(90.32% vs. 68.97%,P<0.05).The improvement time of wheezing, chest tightness and cough after treatment in group A was shorter than that in group B(P<0.05).After treatment, serum eotaxin-2 and IL-33 levels in the two groups were lower than those before treatment, and the levels in group A were lower than those in group B(P<0.05).After treatment, the FVC,FEV1 and PEF in the two groups were increased, and the above indexes in group A were higher than those in group B(P<0.05).Conclusion Budesonide formoterol powder inhalation combined with montelukast sodium is effective in the treatment of patients with acute attack of bronchial asthma, which can effectively improve the clinical symptoms and lung function of patients, and lower serum eotaxin-2 and IL-33 levels.
作者
迟春天
周建
张明春
CHI Chun-tian;ZHOU Jian;ZHANG Ming-chun(Department of Respiratory Medicine,Yiwu Central Hospital,Yiwu 322000,China)
出处
《实用药物与临床》
CAS
2021年第12期1087-1090,共4页
Practical Pharmacy and Clinical Remedies
